On June 7, 2021, the FDA approved aducanumab to treat patients with Alzheimer’s disease . For more information about this new treatment, please click here.
The Cleveland Alzheimer’s Disease Research Center (CADRC) is a National Institute on Aging Center which has the goal of increasing the speed of research being done on aging-related brain disorders. A key activity of the CADRC is a multi-site, observational study in which older individuals both with and without dementia will be followed over time. Participants will be asked to undergo bio-specimen collection, imaging procedures, and cognitive testing on an annual basis. This readily-available data will be used to advance national-level future research, including therapeutic trials.